Search

BACKGROUND: As a skin substitute, acellular dermal matrix has broad prospects and market. OBJECTIVE: To review the clinical application of acellular dermal matrix. METHODS: The authors searched PubMed, CNKI and Wanfang databases for articles published from 2000 to 2021 with the key words of “acellular dermal matrix, reconstruction/repair/plastic/clinical study” in English and Chinese, separately. Finally, 64 articles were included for review. RESULTS AND CONCLUSION: Acellular dermal matrix, characterized by rapid vascularization, low antigenicity, good histocompatibility and stable physicochemical properties, is a commonly used biological material in operations in the head and neck surgery, breast surgery, burn plastic surgery, gynecology, and urology. The main problem lies in its low output and the complicated production process to meet the medical standards. Thus, the price of acellular dermal matrix used in clinical use is high, increasing the medical economic burden of patients. Although most of the alloantigen substances are removed, acellular dermal matrix is still a foreign material for patients, so there is still a risk of surgical complications, such as rejection and infection. For future acellular dermal matrix, it is necessary to optimize the production process, improve the production process, reduce the production cost and increase the commercial specifications. From improving the decellularization process, it further removes proteins and other allergens from the acellular dermal matrix while preserving the dermal matrix, further reduces the immunogenicity of the acellular dermal matrix, enhances its compatibility, and reduces adverse events, such as infection and rejection. [ABSTRACT FROM AUTHOR]

Objective To study the efficacy of pegylated recombinant human granulocyte stimulating factor (PEG-rhG-CSF) in the prevention of neutropenia in breast cancer patients for dose intensive adjuvant chemotherapy and to provide the evidence for the clinical application of PEG-rhG-CSF. Methods 37 women with breast cancer were randomly divided into two groups. The experimental group accepting PEG-rhG-CSF prevention after EC-T chemotherapy and the control group accepting rhG-CSF prevention. The efficiency of PEG-rhG-CSF, the incidence and duration of neutropenia in two groups during six cycles of chemotherapy were monitored. Results 37 patients (22 in the experimental group and 15 in the control group) were enrolled in the clinical observation. The incidence of degree 3 and 4 neutropenia in the experimental group was lower than that in the control group during each chemotherapy cycle, and the difference was statistically significant. The difference between the two groups of time from the end of chemotherapy to the lowest absolute value of neutrophils was not statistically significant (P = 0.51). The difference between the two groups of the duration of degree3 and 4 neutropenia was not statistically significant (P = 0.119).There was no significant difference in the quality of life between the two groups. Conclusion PEG-rhG-CSF can reduce the incidence of degree 3 or 4 neutropenia in breast cancer patients for dose intensive adjuvant chemotherapy and the efficacy is better than rhG-CSF, suggesting that PEG-rhG-CSF has the clinical value. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Kunming Medical University / Kunming Yike Daxue Xuebao is the property of Kunming Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)